Related Experiment Videos
Pharmacologic therapy for the irritable bowel syndrome
1Mayo Clinic Rochester, Charlton Building 8-110, 200 First Street, S.W., Rochester, MN 55905, USA.
The American Journal of Gastroenterology
|May 10, 2003
Summary
Current irritable bowel syndrome (IBS) treatments offer limited relief, with many therapies showing modest efficacy or uncertain benefits. New drugs are in development, but optimal IBS management remains a challenge.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Irritable bowel syndrome (IBS) management presents significant challenges due to the modest efficacy of current treatments.
- Abdominal pain and bowel habit disturbances in IBS are often poorly controlled by standard therapies.
Purpose of the Study:
- To review current and emerging therapeutic options for irritable bowel syndrome (IBS).
- To evaluate the efficacy and limitations of various pharmacological interventions for IBS symptom management.
Main Methods:
- Literature review of existing and investigational therapies for IBS.
- Analysis of clinical trial data and established treatment guidelines for IBS management.
Main Results:
- Antispasmodics offer modest relief for abdominal pain; low-dose tricyclic antidepressants are effective but have limitations.
- Selective serotonin reuptake inhibitors have uncertain efficacy, while loperamide helps diarrhea but not pain.
- Newer agents like alosetron and tegaserod show promise for specific IBS subtypes, but their use is restricted or efficacy in broader populations is unknown.
Conclusions:
- Effective management of IBS remains challenging, with a need for more targeted and efficacious therapies.
- Several drug classes demonstrate limited or specific utility, highlighting the complexity of IBS treatment.
- Ongoing research into novel visceral analgesics and other agents may offer future solutions for IBS patients.